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MigrationProstatic branching morphogenesis is an intricate event requiring precise temporal and spatial integration of
numerous hormonal and growth factor-regulated inputs, yet relatively little is known about the downstream
signaling pathways that orchestrate this process. In this study, we use a novel mesenchyme-free embryonic
prostate culture system, newly available mTOR inhibitors and a conditional PTEN loss-of-function model to
investigate the role of the interconnected PI3K and mTOR signaling pathways in prostatic organogenesis.
We demonstrate that PI3K levels and PI3K/mTOR activity are robustly induced by androgen during murine
prostatic development and that PI3K/mTOR signaling is necessary for prostatic epithelial bud invasion of
surrounding mesenchyme. To elucidate the cellular mechanism by which PI3K/mTOR signaling regulates
prostatic branching, we show that PI3K/mTOR inhibition does not signiﬁcantly alter epithelial proliferation
or apoptosis, but rather decreases the efﬁciency and speed with which the developing prostatic epithelial
cells migrate. UsingmTOR kinase inhibitors to tease out the independent effects ofmTOR signaling downstream
of PI3K,we ﬁnd that simultaneous inhibition ofmTORC1 andmTORC2 activity attenuates prostatic branching and
is sufﬁcient to phenocopy combined PI3K/mTOR inhibition. Surprisingly, however, mTORC1 inhibition alone has
the reverse effect, increasing the number and length of prostatic branches. Finally, simultaneous activation of PI3K
and downstreammTORC1/C2 via epithelial PTEN loss-of-function also results in decreased budding reversible by
mTORC1 inhibition, suggesting that the effect of mTORC1 on branching is not primarily mediated by negative
feedback on PI3K/mTORC2 signaling. Taken together, our data point to an important role for PI3K/mTOR signaling
in prostatic epithelial invasion and migration and implicates the balance of PI3K and downstream mTORC1/C2
activity as a critical regulator of prostatic epithelial morphogenesis.
© 2011 Elsevier Inc. All rights reserved.Introduction
The prostate gland develops from the urogenital sinus (UGS), an
endodermal sac derived from the hindgut. In males and females, the
UGS remains morphologically identical until E17.5 in mice, at which
point branching morphogenesis commences in males under the inﬂu-
ence of androgens produced by the fetal testes (Thomson and Marker,
2006). During prostatic branching, the urogenital sinus epithelium
(UGE) invades the surroundingmesenchyme (UGM) forming epithelial
buds that eventually ramify into a network of interconnected tubules.
Classical studies in the 1970s demonstrated that androgen-mediated
signaling is both necessary and sufﬁcient for this process (Cunha and
Lung, 1978; Takeda et al., 1986). Further, tissue recombination experi-
ments established that the effects of androgens are principallymediatedns Hopkins School ofMedicine,
5, USA. Fax: +1 410 502 9911.
rights reserved.by androgen receptor in the UGM rather than the UGE (Cunha, 1973;
Cunha and Lung, 1978). Although these experiments suggest that para-
crine signaling by theUGM to theUGE regulates prostatic epithelial inva-
sion, the secretedmolecules (“andromedins”) and downstream signaling
pathways responsible for this process remain unclear (Prins and Putz,
2008; Pritchard and Nelson, 2008). Members of the ﬁbroblast growth
factor family, speciﬁcally FGF10 and FGF7, were early candidates for
andromedins because they are secreted by the UGM and act as chemoat-
tractants for the migrating prostatic epithelial cells (Donjacour et al.,
2003; Lu et al., 1999; Sugimura et al., 1996; Thomson, 2001; Thomson
and Cunha, 1999). However, a number of recent studies have suggested
that androgen-induced up-regulation of FGFR2 (the preferred receptor
for FGF7 and FGF10) in theUGEmay underlie the differential responsive-
ness to FGF signaling in males and females (Huang et al., 2005; Lin et al.,
2007; Schaeffer et al., 2008).
Although multiple signaling pathways are known to be activated
downstream of androgen and FGF, it remains unclear how many of
these are required for prostatic development. Recent work has focused
on MAPK (mitogen activated protein kinase) signaling, as FGFR2
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macologic Mek/Erk1,2 inhibition attenuates prostatic branching in vitro
(Huang et al., 2005; Kuslak andMarker, 2007; Zhang et al., 2008). How-
ever, several lines of evidence suggest that PI3K/mTOR (phosphoinosi-
tide-3-kinase/mammalian target of rapamycin) signaling may be an
additional important regulator of prostate development. First, androgen
can directly activate PI3K signaling in androgen-sensitive benign epithe-
lial cells by interactionwith the regulatory p85 subunit of PI3K (Baron et
al., 2004). Second, gene expression studies have documented that andro-
gen induces expression of a number of regulatory members of the PI3K
and mTOR signaling pathways, including Pik3r3 and Rheb in embryonic
prostate tissue (Schaeffer et al., 2008). Third, androgen indirectly acti-
vates PI3K signaling in the prostate via FGF signaling since PI3K signaling
is also compromised in the prostates of mice with genetic inactivation of
FGFR2 (Zhang et al., 2008). Finally, and perhaps most importantly, PI3K/
mTOR signaling is commonly aberrantly activated in prostate cancer and
a number of recent gene expression studies have suggested that the sig-
naling and transcriptional programs operative during prostatic tumori-
genesis and embryonic development are strikingly similar (Pritchard et
al., 2009; Schaeffer et al., 2008).
The PI3K andmTOR signaling pathways are intricately interconnected
andmodulate a number of cellular processes critical for embryonic devel-
opment and tumorigenesis. Upon activation, PI3K phosphorylates PIP2
(phosphatidylinositol [4,5]-bisphosphate) to PIP3 (phosphatidylinositol
3,4,5]-trisphosphate) allowing the recruitment of a number of PH-
domain containing signaling effectors to the cell membrane, including
the kinase PDK1 and its substrate AKT. Importantly, PI3K activity is op-
posed by lipid phosphatases, the best characterized of which is PTEN
(phosphatase and tensin homologue). AlthoughAKT is partially activated
following phosphorylation on the Thr308 residue by PDK1, for full activa-
tion, AKT must be independently phosphorylated on Ser473 by mTOR
(Guertin et al., 2006). This makes mTOR signaling simultaneously up-
stream and downstream of AKT becausemTOR kinase exists in two com-
peting complexes, mTORC1 (indirectly activated by AKT) and mTORC2
(which phosphorylates AKT at Ser473) (Bhaskar and Hay, 2007; Guertin
and Sabatini, 2007). Once phosphorylated at both Thr308 and Ser473,
AKT is fully activated and may phosphorylate a number of substrates,
resulting in diverse cellular outcomes, including cell proliferation, apo-
ptosis and migration (Guertin and Sabatini, 2007).
Despite its established role in numerous cellular processes critical for
embryonic development and epithelial tumorigenesis, relatively few
prior studies have looked at the role of PI3K/mTOR signaling in verte-
brate branching morphogenesis and no studies have speciﬁcally exam-
ined its role in prostate development. In the kidney, inhibition of PI3K/
mTOR completely blocks epithelial branching in organ cultures and sim-
ilarly blocks the GDNF-dependent emergence of ectopic ureteric buds in
vitro, likely by inhibiting GDNF-stimulated directed cell migration, as
seen in kidney cell line model systems (Tang et al., 2002). In the lung,
PI3K/mTOR inhibitors decrease epithelial bud number and length by in-
creasing apoptotic activity and decreasing proliferative activity
(Wang et al., 2005). In the submandibular salivary gland, PI3K/
mTOR inhibition dramatically attenuates epithelial clefting in organ cul-
ture and mesenchyme-free epithelial cultures (Larsen et al., 2003). This
phenotype does not appear to be mediated by effects on proliferation,
however the cellular mechanism has not been fully elucidated. Finally,
in the Mullerian duct, PI3K/mTOR signaling is required for elongation of
the duct tip and cellular proliferation, but is not required for cellmigration
(Fujino et al., 2009). Themost important theme emerging from this work
is that PI3K/mTOR signaling is required for epithelial budding in a number
of different systems. However, the cellular mechanisms responsible for
this phenotype are varied and tissue-speciﬁc. Furthermore, because
most experiments have utilized pharmacologic inhibitors that simulta-
neously target both PI3K and mTOR kinase, it remains unclear which of
these interconnected signaling modules mediates this phenotype.
In the present study, we take advantage of a novel mesenchyme-
free prostate epithelial culture system and newly available speciﬁcmTOR kinase inhibitors to investigate the roles of PI3K and mTOR sig-
naling in prostatic branching morphogenesis. We ﬁnd that PI3K/
mTOR activity is up-regulated and required in the urogenital sinus
epithelium for prostatic bud invasion into the surrounding mesen-
chyme. Consistent with a conserved role for this pathway in the reg-
ulation of cellular motility, inactivation of PI3K/mTOR signaling does
not signiﬁcantly impact cellular proliferation or apoptosis, but rather
decreases the efﬁciency and speed of epithelial cell migration in re-
sponse to growth factor stimulation. Using mTOR kinase inhibitors to
dissect out the contribution of downstreammTOR signaling to prostat-
ic branching, we ﬁnd that while combined inhibition of mTORC1 and
mTORC2 phenocopies the effects of PI3K/mTOR inhibition, inhibition
of mTORC1 alone enhances prostatic branching. Importantly, simulta-
neous activation of PI3K and downstream mTORC1 and mTORC2 by
early embryonic PTEN loss-of-function also results in decreased pros-
tatic epithelial budding. Taken together, these data suggest that the
balance of PI3K and downstream mTORC1/mTORC2 activity plays a
key role in modulating prostatic branching morphogenesis.
Material and methods
Mouse lines
Animal protocols were approved by the Johns Hopkins University
Animal Care and Use Committee (protocol #MO08M367). All mouse
lines were maintained on a C57BL/6 background. PH-Akt-GFP mice
were a kind gift of Takehiko Sasaki (Sasaki et al., 2007).mT/mG reporter
mice were obtained from Jackson Laboratory (Muzumdar et al., 2007,
Bar Harbor, ME) and crossed with R26ERCre mice (Badea et al., 2003,
Jackson Laboratory) to determine timing and localization of Cre expres-
sion during in vitro culture with 4-OHT (4-hydroxytamoxifen) expo-
sure. Mice with inducible PTEN loss of function were generated by
crossing R26CreER and PTENloxp/loxp mice (Lesche et al., 2002, Jackson
Laboratory) to obtain R26CreER;PTENloxp/loxp mice (referred to in the
text as PTEN−/− following in vitro culture in 4-OHT) and PTENloxp/loxp
littermates (referred to in the text as PTEN+/+ following in vitro cul-
ture in 4-OHT).
Inhibitors and reagents
PI3K ormTOR inhibitors were dissolved in DMSO and added to organ
culture media (described below) at concentrations spanning the IC50
values as follows: LY294002 (10 μM or 25 μM; Sigma-Aldrich; St. Louis,
MO); wortmannin (5 μM; Sigma-Aldrich), PI-103 (100 nM; Axon Med-
Chem, Netherlands); rapamycin (200 nM; Invitrogen; Camarillo, CA),
DMK-1 (also known as compound 13; Ballou et al., 2007; Grifﬁn et al.,
2005; 80 μM; a generous gift from JD Powell) and torin1 (Thoreen et
al., 2009; 500 or 1000 nM; a kind gift from DM Sabatini). Antibodies uti-
lized for immunoblotting and immunohistochemistry were as follows:
anti-110α, p110β, p-AKT(T308), p-AKT(S473), p-p70S6K, AKT, p70S6K,
PTEN, cleaved caspase-3 (all rabbit monoclonals from Cell Signaling
Technologies; Danvers,MA); anti-BrdU (sheeppolyclonal fromFitzgerald
Industries; Concord,MA); anti-CK14 (mousemonoclonal fromMillipore;
Billerica, MA); anti-AE1/AE3 (mouse monoclonal from Ventana; Tucson,
AZ); anti-NKX3.1 (rabbit polyclonal; Chen et al., 2005; a kind gift of CJ
Bieberich); anti-p63 (mousemonoclonal fromSanta Cruz Biotechnology;
Santa Cruz, CA); and anti-K8 (rat polyclonal developed by P. Brulet and
R. Kemler; obtained from the Developmental Studies Hybridoma Bank
developed under the auspices of the NICHD and maintained by The
University of Iowa, Department of Biology, IA).
Organ culture
Mouse pregnancies were timed according to scheduled 10-hour
male–female pairings. Embryos were dissected at indicated times
(E15.5–P4) and the sex determined by gonadal inspection. Following
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urogenital sinuses (UGS) were cultured for 1–14 days as indicated
at 37 °C on 0.4 μm membranes (Millipore; Bedford, MA) overlying
completely deﬁned serum-free organ culture media [DMEM/F12 (1:1)
supplemented with 1% of nonessential amino acids (Cellgro; Manassas,
VA), 0.01 mg/ml of apo-transferrin (Sigma-Aldrich), 0.01 mg/ml of in-
sulin (Sigma-Aldrich), 1×10−8 M dihydrotestosterone (DHT) (Sigma-
Aldrich), 1 g/L of D-glucose (Sigma-Aldrich), 2 mM L-glutamine (Invi-
trogen) and 1% of 10 μg/mL penicillin/streptomycin (Invitrogen)].
Media containing inhibitors or DMSO vehicle were generally replaced
every 24–48 h during the culture period. To evaluate the role of andro-
gen on branching, E15.5 female UGSs were cultured in standard organ
culturemediawith orwithout DHT for 48 h and processed for immuno-
blotting as below. For experiments involving inducible PTEN loss of
function, control (PTEN+/+) and experimental (PTEN−/−) UGSs
were cultured in organ culture media lacking DHT with 6 μM 4-OHT
for 48 h followed by standard organ culture media with DHT and 6 μM
4-OHT for the subsequent 5–12 days. In all experiments, a minimum
of 3–5 UGSs were treated per condition. Following organ culture,
UGSs were imaged on a Motic SMZ 168 stereomicroscope (Motic
Optics; Richmond, British Columbia) equipped with a Moticam 2300,
3.0 megapixel digital color camera. Brancheswere counted fromphoto-
micrographs and branch length was measured for each branch using a
scaled reference measurement.
PIP3 localization in vivo
For histology, UGS tissue from P4 PH-Akt-GFPmice was immediate-
ly ﬁxed in 4% paraformaldehyde for 6–8 h and cryopreserved in 20%
sucrose in PBS overnight, embedded in OCT media and snap-frozen at
−80 °C. 4 μm sections were prepared by standard cryosectioning tech-
nique, rinsed in PBS and nuclei were stained with DAPI-containing
mounting media (Invitrogen). Membranous GFP localization was visu-
alized on a Zeiss LSM510 Meta laser scanning confocal microscope
(Carl Zeiss; Oberkochen, Germany).
Immunoblotting
Whole UGS tissues were homogenized and lysed in ice-cold modi-
ﬁed RIPA buffer (1× PBS, 1% IGEPAL CA-630 [v/v], 0.1% SDS [w/v], 0.5%
Na Deoxycholate [w/v]) supplemented with PMSF (1 mM), aprotinin
(1 TIU/ml), NaVO4 (1 mM), NaF (1 mM) and one protease inhibitor tab-
let (Roche Diagnostics; Mannheim, Germany) in 7 ml buffer for 10 min
on ice. Protein concentrationswere quantiﬁed using theMicro BCA Pro-
tein Assay Kit (Pierce; Rockford, IL), and 15 μg of protein were loaded
per lane on a 7.5% Tris–HCl SDS-PAGEgel (BioRad;Hercules, CA). Protein
was transferred to nitrocellulose membrane (Amersham Bioscience;
Buckinghamshire, UK). Membranes were allowed to block for 1 h at RT
in 5% nonfat milk in 1XTBS-T and then incubated overnight with a pri-
mary antibody diluted in 1% BSA. Antibody dillutions were as follows:
p-AKT(T308) (1:1000), p-AKT(S473) (1:1000), p-p70S6K (1:1000),
p110α (1:1000), p110β (1:1000), pan-AKT (1:1000), p70S6K (1:1000)
andβ-actin (1:4000) (all from Cell Signaling Technologies). The second-
ary antibodies used were anti-rabbit or anti-mouse immunoglobulin as
appropriate (Cell Signaling) and diluted at 1:2000 in 1% BSA. Gel loading
was assessed by blotting forβ-actin. Blotswere developed using a chemi-
luminescent development solution (Super Signal West Femto; Pierce)
and bands were imaged on a chemiluminescent imaging system (Alpha
Innotech; Santa Clara, CA). Digital images were quantiﬁed using back-
ground correction on the Alpha Innotech system and all bandswere nor-
malized to their respective β-actin levels.
Immunohistochemistry/immunoﬂuorescence
Following ﬁxation in 10% neutral buffered formalin (Sigma-
Aldrich) and standard tissue processing, embedding, and sectioningat 4 μm, slides were deparafﬁnized and rehydrated and equilibrated
brieﬂy in water. Antigen unmasking was performed by steaming in cit-
rate buffer (pH 6.0) for 25 min for all antibodies except NKX3.1, which
was unmasked in EDTA (pH 9) for 45 min. Endogenous peroxidase
activity was quenched by incubation with peroxidase block for 5 min
at room temperature. Non-speciﬁc binding was blocked by incubating
in 1% bovine serum albumin (BSA) in TBST for 20 min at room temper-
ature. Sections were incubated with each antibody overnight at 4 °C.
Antibodies were diluted in 1% BSA as follows: p110α (1:400), p-AKT
(S473) (1:50), BrdU (1:2000), cleaved caspase3 (1:200), K14 (1:100),
AE1/AE3 (prediluted) andNKX3.1 (1:1500). For immunohistochemistry,
a horseradish peroxidase-labeled polymer (ImmPress; Vector Laborato-
ries, Burlingame, CA or PowerVision; Leica Microsystems, Bannockburn,
IL for NKX3.1) was applied for 30 min at room temperature. Signal detec-
tion was performed using 3,3′-diaminobenzidine tetrahydrochloride
(DAB) as the chromagen (Vector Laboratories). Slides were counter-
stained with hematoxylin, dehydrated, and mounted. For immunoﬂuo-
rescence, Alexaﬂuor-594 anti-mouse (Invitrogen) or DyLight-549 anti-
rat (Jackson Immunoresearch, West Grove, PA) secondary antibodies
were applied at 1:200 for 30 min. Coverslips weremountedwith Prolong
Antifade containing DAPI (Invitrogen).
Proliferation and apoptosis assays
For 5-bromo-2′deoxyuridine (BrdU) labeling studies, E15.5 UGSs
were cultured in standard media with 25 μM LY294002 or DMSO
(vehicle). On day 4 of culture, fresh media containing 10 μM BrdU
(BD Bioscience, San Jose, CA) was added. Following a 2 h incubation
period, samples were immediately ﬁxed overnight in 10% neutral
buffered formalin and processed for immunohistochemistry. BrdU
immunohistochemistry was scored manually by counting the
proportion of positively stained nuclei in each ductal branch. At least
7 UGSs were analyzed for each condition.
To assess the rates of apoptosis, E15.5 UGSs were dissected and
cultured in standard media with 25 μM LY294002 or DMSO (vehicle).
Cultures were ﬁxed in 10% neutral buffered formalin overnight on day
4 of culture and processed for caspase 3 immunohistochemistry. At
least 7 UGSs were analyzed for each condition.
Mesenchyme-free culture
Male UGS tissue from R26ERCre */0; mT/mG*/0 mice was dissected
at E15.5 and incubated in 2 U/mL dispase (Invitrogen) in HBSS at 37 °C
for 15 min. Following washing in ice-cold HBSS, the mesenchyme was
manually removedwith ﬁne surgical instruments under a dissectingmi-
croscope. The remaining intact urogenital sinus epithelium (UGE) was
embedded in growth-factor reduced Matrigel (BD Biosciences) in a 4-
well coverglass-bottom tissue culture dish (ThermoScientiﬁc, Rochester,
NY) and submerged in DMEM/F12 media supplemented with
1×10−8 M DHT, 1% penicillin/streptomycin, 1% insulin–transferrin–
selenium solution (Sigma Aldrich), 500 ng/mL FGF10 and 200 ng/mL
FGF7 (Peprotech, Rocky Hill, NJ). Tissues were immediately incubated
on the heated-CO2 controlled stage of a Zeiss AxioObserver inverted
microscope with ﬂuorescence and phase contrast and equipped with
anAxioCamdigital camera (Carl Zeiss). Differential interference contrast
(DIC) and epiﬂuorescence images were collected at 10 μm intervals
using a long-working distance 20× objective every 60 min for 50–60 h.
Following imaging, tissues were ﬁxed in 10% neutral buffered formalin
and submitted for histologic sectioning followed by standard hematoxy-
lin and eosin (H&E) staining.
3D cell motility analysis
Movies collected from mesenchyme-free cultures were analyzed
using Imaris 6.3 image analysis software (Bitplane, Zurich, Switzerland).
EGFP-expressing cells were marked automatically and tracked in three
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mean speed were calculated. A minimum of 8 UGSs were analyzed per
condition.Results
PI3K is up-regulated and active in the developing prostate following an-
drogen stimulation
To determine whether PI3K is present and active in the developing
prostate, we took advantage of a well-characterized organ culture
system to initiate prostate budding from male or female urogenital
sinus (UGS) tissues following in vitro androgen exposure (Doles et
al., 2005; Lipschutz et al., 1997; Martikainen and Suominen, 1983;
Trowell, 1959). Androgen-naïve E15.5 female UGSs were cultured in
vitro for 48 h in the presence or absence of dihydrotestosterone
(DHT), a potent androgen (Fig. 1A). Androgen exposure increased
p-AKT (T308) levels, an indirect measure of PI3K activity, and
resulted in variable up-regulation of the p110α and p110β catalytic
subunits of PI3K by immunoblotting (Fig. 1B; n=3 independent
experiments, 3 UGS/condition/experiment). In contrast to total levels
in the mesenchyme and epitheliummeasured by immunoblot, immu-
nohistochemistry revealed prominent enrichment of p110α speciﬁ-
cally in the invading epithelial bud in vivo in E17.5 and E18.5 male
embryos (Fig. 1C, top left panel). Interestingly, p-AKT(S473), a mea-
sure of PI3K and downstream mTORC2 activity, was also up-
regulated in the invasive prostatic buds in E18.5 male embryos
(Fig. 1C, top right panel). Because p-AKT levels provide only an indi-
rect measure of PI3K activity, we took advantage of a mouse trans-
genic for the PIP3 biosensor AKT-PH-GFP to assess in vivo PIP3 levels
directly (Sasaki et al., 2007). The emerging prostatic buds in P4 em-
bryos from these mice showed increased membranous GFP signalFig. 1. PI3K is up-regulated and active during prostatic branching morphogenesis. (A) Immunob
testosterone (DHT) for 48 h reveals mild up-regulation of p-AKT (T308), an indirect measure
in response to androgen exposure. (B) Quantiﬁcation of immunoblot in (A); n=3 independ
E18.5 male UGS tissues demonstrates enrichment of p110α and downstream p-AKT(S473) pr
compared to surrounding urethral epithelium. Mice transgenic for the PIP3 biosensor, AKT-P
at P4 (bottom panels, arrows, 100× and 400× magniﬁcation).compared to the surrounding urethral sinus epithelium (Fig. 1C, bot-
tom panels), indicating that PI3K is active in the epithelium. From
these experiments, we conclude that PI3K and mTORC2 are enriched
and active in the invading prostatic buds, indicating that this signal-
ing pathway plays an important role in epithelial invasion during
prostatic branching morphogenesis.PI3K/mTOR activity is required for prostatic budding in vitro
Next, we sought to determine whether PI3K/mTOR activity is
required for prostatic morphogenesis. PI3K consists of multiple cata-
lytic and regulatory subunits and homozygous deletion of either
p110α or p110β is embryonic lethal (Bi et al., 1999, 2002). Further
complicating the situation, loss of one isoform often alters expression
of another, making genetic experiments resulting in conditional PI3K
loss-of-function technically challenging (Brachmann et al., 2005; Ueki
et al., 2002, 2003; Zhao et al., 2006). Thus, to determine whether
there is a requirement for PI3K signaling during prostatic branching
morphogenesis, we took advantage of three pharmacologically dis-
tinct inhibitors for this pathway. LY294002, wortmannin and PI-103
are well-characterized inhibitors of PI3K, however because of catalyt-
ic site homology, these inhibitors also block downstream mTOR
kinase activity (Brunn et al., 1996; Knight et al., 2006). To assess the
effects of combined PI3K/mTOR signaling blockade, urogenital sinus
(UGS) tissues from E15.5 mice were cultured with inhibitor or vehicle
in the presence of androgen for 7 days. UGS tissues exposed to 10–25 μM
LY294002 showed a striking, consistent and dose-dependent attenua-
tion in prostatic branching with minimal phenotypic variability
(Fig. 2A, Supplementary Fig. 1). Interestingly, the UGS epithelium of
LY294002-treated samples did expand over the culture period relative
to its size at day 0, but without apparent epithelial budding. Immuno-
blots demonstrated that these concentrations of inhibitor resulted in alotting of E15.5 female urogenital sinus (UGS) tissues cultured with or without dihydro-
of PI3K signaling, with a variable increase in levels of the p110α catalytic subunit of PI3K
ent experiments, 3 UGS/condition/experiment. (C) Immunohistochemistry of E17.5 and
oteins in the invasive prostatic epithelial buds (top panels, arrows, 200×magniﬁcation)
H-GFP, show enrichment of membranous PIP3 in the emerging prostatic bud epithelium
Fig. 2. PI3K/mTOR signaling is required for prostatic branching morphogenesis. (A) Treatment of E15.5 male urogenital sinus (UGS) tissues with LY294002, wortmannin and PI-103
(PI3K/mTOR inhibitors) for 7 days in organ culture results in a decrease in prostatic epithelial budding (arrowheads) compared to vehicle control. Scale bar=1 mm. (B) Immuno-
blotting of UGS lysates following 24 h of treatment with vehicle or LY294002 reveals a decrease in PI3K signaling (indirectly measured by p-AKT [T308] levels), mTORC1 signaling
(p-p70S6K levels) and mTORC2 signaling (p-AKT [S473] levels). (C) Quantiﬁcation of immunoblot results from (B); n=3 independent experiments, 3 UGS/condition/experiment.
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p-AKT(S473)which reﬂectsmTORC2 and PI3K signaling (Figs. 2B and C).
Phospho-p70S6K levelswere also decreased, reﬂecting decreased down-
streammTORC1 signaling as well. Wortmannin, an irreversible inhibitor
of PI3K and mTOR kinase, similarly attenuated prostatic branching
(Fig. 2A) and had a nearly identical proﬁle on immunoblotting (data
not shown). Finally, PI-103, an additional newly available and speciﬁc
inhibitor of PI3K and mTOR had a similar phenotypic effect to
LY294002 and wortmannin (Fig. 2A). Although experiments with phar-
macologic inhibitors must always be interpreted with caution, the fact
that we observed identical results with three pharmacologically distinct
inhibitors strongly suggests that PI3K/mTOR signaling is required for
prostatic branching morphogenesis.
To assess whether the morphologic effects of PI3K/mTOR inhibi-
tors on prostatic branching were due to toxicity, we performed drug
washout experiments. Exposure to 25 μM LY294002 for 24 h followed
by washout and replacement with vehicle-containing media resulted
in prostatic branching similar to vehicle treated controls, conﬁrming
that this concentration of LY294002 does not result in non-speciﬁc
epithelial or mesenchymal toxicity (Fig. 3A). Histologic examination
of UGS tissues treated with vehicle or LY294002 for 7 days veriﬁed
that both the epithelial and mesenchymal compartments appeared
viable (Fig. 3B). However, tissues treated with PI3K/mTOR inhibitors
had a near total absence of the invasive ﬁnger-like epithelial buds
interspersed with strands of mesenchymal tissue seen in the vehicle
control samples. Instead, PI3K/mTOR-inhibited tissues showed abroad-based, pushing epithelial border with the mesenchyme,
highlighted by pan-keratin immunostaining (Fig. 3B). Quantitation
of bud number and size revealed a nearly four-fold decrease in epi-
thelial bud number with PI3K/mTOR inhibition and a signiﬁcant
decrease in bud length for the few buds that were seen (Fig. 3C;
n=10–11 UGS/condition). Histologic examination of the prostate
buds also suggested that the epithelial nuclei were more crowded in
the samples treated with PI3K/mTOR inhibitor and quantitative anal-
ysis revealed that there were signiﬁcantly more epithelial nuclei per
unit area in the LY294002-treated samples compared to vehicle con-
trol, resulting in the appearance of epithelial disorganization (Fig. 3D;
n=10–11 UGS/condition). Taken together, these data indicate that
PI3K and/or mTOR signaling is required for epithelial duct invasion
into surrounding mesenchyme as well as for duct elongation during
prostatic branching morphogenesis.
PI3K/mTOR activity is not required for prostate epithelial cell proliferation,
apoptosis or speciﬁcation
Next, we sought to determine the cellularmechanismbywhich PI3K/
mTOR inhibition attenuates prostatic branching. Although both PI3K and
mTOR signaling have established roles in cell proliferation and inhibition
of apoptosis (Bhaskar and Hay, 2007; Guertin and Sabatini, 2007), work
in multiple organ systems suggests that the cellular mechanism by
which PI3K/mTOR signaling inhibits branching morphogenesis is varied
and tissue-speciﬁc (Fujino et al., 2009; Larsen et al., 2003; Tang et al.,
Fig. 3. PI3K/mTOR inhibition is not toxic and results in fewer and shorter invasive prostatic buds. (A) Treatment of male E15.5 urogenital sinus (UGS) tissue with 25 μM LY294002 for
24 h followed by drug washout restores prostatic branching compared to UGS tissues treated for 7 days and vehicle controls. Scale bar=1 mm. (B) Histologic examination of E15.5
UGS tissues treated with LY294002 for 7 days in organ culture reveals a near total absence of the invasive ﬁnger-like epithelial buds interspersed with strands of mesenchyme seen
in the vehicle control samples, and instead shows broad-based, pushing protrusions into the mesenchyme using hematoxylin and eosin (H&E) staining (buds indicated by black
outlines, 100× magniﬁcation). Buds are highlighted by pan-keratin (AE1/AE3) immunostaining (200× magniﬁcation). Epithelial nuclei appear more crowded in the LY294002-
treated samples (400× magniﬁcation). (C and D) Quantiﬁcation of mean bud number, bud length and nuclear density in LY294002-treated samples reveals a statistically signiﬁcant
decrease in bud number and length and increase in nuclear density (n=10–11 UGS per condition, error bars=standard error of the mean (SEM), p-values using Student's t-test for
unpaired samples with unequal variance are indicated).
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tatic buddingwith PI3K/mTOR inhibitionwas due to decreased epithelial
proliferation, we used BrdU labeling to quantify proliferating cells on day
4 of in vitro urogenital sinus culture. In the presence of both vehicle and
inhibitor, proliferating cells were essentially conﬁned to the urogenital
sinus epithelium in the region of the emerging prostatic buds (Fig. 4A,
left panel). Interestingly, quantiﬁcation of the percentage of epithelial
cellswith BrdU labeling did not reveal a signiﬁcant difference in the pres-
ence of PI3K/mTOR inhibitors (Fig. 4B; n=7–9 UGS/condition). Apopto-
sis rates were assessed by immunohistochemical staining for cleaved
caspase 3 at day 4 of culture. In both vehicle control- and LY294002-
treated samples, apoptotic cellswere virtually absent from theurogenital
sinus epithelium, although rare apoptotic cells were seen in the sur-
rounding mesenchymal tissue in both cases and provided an internal
positive control (Fig. 4A, middle panel). Thus, we conclude that de-
creases in proliferation or increases in apoptotic activity do not primarily
account for the effects of PI3K/mTOR inhibitors on prostatic epithelial
branching.
Genetic loss-of-function models that inhibit prostatic epithelial cell
speciﬁcation during development result in a similar attenuated branching
phenotype to that seen with PI3K/mTOR inhibitors (BWS and DMB,
unpublished data). To investigate whether the decrease in prostatic
ductal branchingmight be due to a lack of prostatic epithelial differentia-
tion, we performed immunostaining for NKX3.1, an androgen-regulated
homeodomain-containing transcription factor. Up-regulation of NKX3.1
is one of the earliest known molecular markers of prostatic epithelial
speciﬁcation (Bhatia-Gaur et al., 1999; Bieberich et al., 1996). Interesting-
ly, both vehicle control and PI3K/mTOR-inhibited tissues showed robust
nuclear NKX3.1 expression conﬁned to the emerging or abortive prostaticepithelial buds (Fig. 4A, right panel). Thus, we conclude that PI3K/mTOR
activity is not required for prostatic epithelial speciﬁcation.
PI3K/mTOR activity is speciﬁcally required in prostatic epithelial cells
during branching morphogenesis
Many of themorphogenic signals regulating prostatic epithelial devel-
opment are paracrine signals from the urogenital sinus mesenchyme
(Prins and Putz, 2008), so we considered the possibility that PI3K/mTOR
inhibition attenuated prostatic epithelial branching by inhibiting mesen-
chymal signaling. To examine the speciﬁc effects of PI3K/mTOR inhibition
ondeveloping prostatic epithelial cells,wedeveloped amesenchyme-free
embryonic epithelial culture system that supports prostatic epithelial
branching, similar to systems previously described for the study of sali-
vary gland, lung and mammary morphogenesis (Hahm et al., 1990;
Nogawa and Ito, 1995; Nogawa and Takahashi, 1991). Using a combina-
tion of enzymatic and manual dissection, we dissociated the urogenital
sinus epithelium from the mesenchyme in E15.5 embryos and embed-
ded the intact epithelial structure in laminin-rich extracellular matrix
(Matrigel). While media containing only androgen led to cystic atrophy
of the epithelium, addition of androgen with FGF10 and FGF7 sup-
ported prostate branching in the absence of mesenchymal tissue
over a 48 h period (Figs. 5A and B). These mesenchyme-free epithelial
explants expressed NKX3.1, consistent with prostatic differentiation
(Fig. 5B), and maintained minimally overlapping basal and luminal
cell layers (expressing p63 and K8, respectively; Fig. 5C), similar to
mature prostate tissue. When viewed by time-lapse differential inter-
ference contrast (DIC) imaging, the Matrigel-embedded urogenital
sinus epithelium branched in an identical pattern in 5 independent
Fig. 4. PI3K/mTOR activity is not required for epithelial proliferation, apoptosis or speciﬁcation. (A) E15.5 male and female UGS tissues were cultured for 4 days in vehicle or 25 μM
LY294002 and treated with BrdU for 2 h prior to ﬁxation. BrdU-positive epithelial nuclei are localized to epithelial buds in both LY294002- and vehicle-treated specimens (left
panels, 200× magniﬁcation). Immunohistochemistry for cleaved caspase-3 using the same specimens reveals a total absence of apoptotic epithelial cells in both conditions,
although rare apoptotic mesenchymal cells are present in vehicle- and LY294002-treated controls and serve as an internal positive control (middle panels, arrows, 400× magniﬁ-
cation). Finally, immunohistochemistry for NKX3.1, an androgen-induced homeobox domain-containing transcription factor expressed during early prostatic development, shows
positive nuclei conﬁned to the emerging prostatic buds in both vehicle- and LY294002-treated specimens, suggesting that appropriate prostatic epithelial cell speciﬁcation occurs in
the presence of PI3K/mTOR inhibition (right panels, 200× magniﬁcation). (B) Quantiﬁcation of proportion of BrdU-positive cells/epithelial bud in vehicle- and LY294002-treated
specimens reveals no statistical difference between the two conditions (n=7–9 UGS/condition, error bars=SEM, p-value using Student's t-test for unpaired samples with unequal
variance).
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within the ﬁrst 24 h after exposure to FGF10 and FGF7 (Fig. 5D, arrows).
In contrast, PI3K/mTOR inhibition in this system resulted in only
small, abortive epithelial branches without evident prostate lobe for-
mation as observed by time-lapse DIC imaging (Fig. 5D, Movies 1A
and 1B). Consistent with our ﬁnding that PI3K is up-regulated and
expressed in the emerging epithelial buds (Fig. 1C), these data support
a speciﬁc requirement for PI3K/mTOR activity in the prostatic epithe-
lium during branching.
PI3K/mTOR activity is required for epithelial motility during branching
morphogenesis
PI3K signaling has a well-established role in the regulation of sin-
gle cell motility and chemotaxis (Kolsch et al., 2008) and an equally
important role is emerging for mTORC2 in these systems (Cai et al.,
2010; Charest et al., 2010; Liu et al., 2010), so we considered the pos-
sibility that PI3K/mTOR inhibition might decrease prostatic epithelial
migration during branching. The fact that prostate epithelial prolifer-
ation is unaffected by PI3K/mTOR inhibition, while epithelial cell den-
sity is increased also suggested that PI3K/mTOR activity may be
required for epithelial motility. To examine three-dimensional pros-
tatic epithelial motility during morphogenesis in intact tissues, we
performed time-lapse imaging experiments using transgenic mouse
tissues mosaic for membranous EGFP expression. Fortuitously, Cre
expression in the R26ERCre mouse line is tightly regulated, and
when crossed to the mT/mG reporter line, R26ERCre;m/TmG mice
show a low level of Cre expression in the absence of 4-OHT exposure.
Accordingly, we observed a small population of EGFP-expressing cells
(b1%) in the urogenital sinus epithelium at E15.5 without 4-OHT.
Timelapse epiﬂuorescence imaging of mesenchyme-free urogenital
sinus epithelial cultures from these mice revealed abundant epithelial
cell motility during prostatic branching, with visible extension and
retraction of cytoplasmic protrusions during this process (Fig. 6A,
top panels and Movie 2A). In the presence of PI3K/mTOR inhibition,
prostatic epithelial cells assumed an elongated morphology com-
pared to vehicle control cells, and though they exhibited cytoplasmicprotrusions, their motility appeared signiﬁcantly impaired (Fig. 6A,
bottom panels and Movie 2B).
To quantify epithelial motility, we used image analysis software to
track the position of individual prostatic epithelial cells in three dimen-
sions over time duringmesenchyme-free morphogenesis (Fig. 6B). This
analysis revealed that PI3K/mTOR inhibition results in a statistically sig-
niﬁcant decrease in epithelial motility asmeasured by net displacement
andmean epithelial cell speed (Fig. 6C). Compared to net displacement,
total distance traveled was less affected in LY294002-treated samples,
indicating that the efﬁciency of epithelial motility is relatively more
compromised than overall motility in PI3K/mTOR-inhibited samples.
Taken together, these data indicate that regulation of cellular migration
contributes to the cellular mechanism by which PI3K/mTOR activity
regulates prostatic branching.
mTOR kinase activity is required for prostatic branching
Because LY294002, wortmannin and PI-103 all inhibit PI3K as well
as mTOR kinase, these data do not distinguish whether the effects of
these drugs are primarily modulated by PI3K or by downstream
mTOR kinase inhibition. Given the emerging role of mTORC2 in single
cell motility (Cai et al., 2010; Charest et al., 2010; Liu et al., 2010), we
hypothesized that speciﬁc inhibition of mTOR signaling, without inhibi-
tion of upstream PI3K signaling, might be sufﬁcient to abrogate prostat-
ic branching. To address this question, we took advantage of a number
of recently described ATP-competitive inhibitors that block mTOR
kinase function without inhibiting PI3K (Ballou et al., 2007; Grifﬁn
et al., 2005; Thoreen et al., 2009). These inhibitors block mTORC1 and
mTORC2 signaling simultaneously, as both complexes require mTOR
kinase for catalytic activity. Treatment of embryonic urogenital sinuses
with torin1 or DMK-1 resulted in markedly decreased branching, phe-
notypically replicating the results seen with combined PI3K/mTOR inhi-
bition by LY294002 (Fig. 7A; images are representative of 3 independent
experiments; concentrations used were 1000 nM for torin1 and 80 μM
for DMK-1). Upon histologic sectioning, urogenital sinuses treated
with mTOR kinase inhibitors showed abortive branches without inva-
sion of the surrounding mesenchymal tissues, nearly identical to
Fig. 5. PI3K/mTOR activity is required speciﬁcally in epithelial cells. (A) A combination of enzymatic and manual dissection allows dissociation of intact urogenital sinus epithelium
(UGE) from mesenchymal tissue and epithelial branching following 48 h of culture in Matrigel with androgen (DHT, 1×10−8 M) and FGF10 (500 ng/mL) and FGF7 (200 ng/mL).
(B) Hematoxylin and eosin (H&E) staining of UGE cultures shows individual epithelial buds surrounded by a prominent basal cell layer, with most cells expressing NKX3.1, a pros-
tatic differentiation marker (200×; inset at 400× magniﬁcation). (C) Immunoﬂuorescence for K8 demonstrates that most interior cells are luminal cells, while exterior cells pre-
dominantly express basal marker p63 with minimal overlap between these populations in merged images (600× magniﬁcation). (D) Time-lapse DIC microscopy of
mesenchyme-free UGE cultures demonstrates the emergence of large prostatic buds in the distribution of the anterior and ventral prostate lobes (arrows) in the vehicle control
(arrows, top panels), while only small and abortive buds are visible in the 25 μM LY294002-treated specimens (arrowheads, bottom panels). Scale bars=100 μm. Images shown
are representative of one experiment (n=5).
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LY294002, these inhibitors did not show consistently graded phenotypic
effects with decreased dosages (e.g., 500 nM for torin1 or 40 μM for
DMK-1), but rather showed a signiﬁcant decrease in branching only at
doses coinciding with ~50% inhibition of both mTORC1 (as measured
by p-p70S6K levels) and mTORC2 activity (as measured by p-AKT
[S473]), without effects on PI3K activity (indirectly measured by p-
AKT[T308] levels) (1000 nM for torin1 and 80 μM for DMK-1; Figs. 7C
and D). This may reﬂect the fact that long term treatment with lower
doses of mTOR kinase inhibitors (e.g., less than 250 nM for torin1 in
cell line experiments) does not effectively inhibit mTORC2 activity and
may even increase PI3K activity (Guertin and Sabatini, 2009). The fact
that inhibition of mTOR kinase alone is sufﬁcient to phenocopy the
effects of dual PI3K/mTOR kinase inhibition implies that mTOR kinase
may be a critical downstream effector of PI3K signaling during branch-
ing morphogenesis.
mTORC1 inhibition results in increased prostatic branching
By deﬁnition, mTOR kinase inhibitors block both mTORC1 and
mTORC2 signaling. To determine whether mTORC1 or mTORC2 signal-
ing is speciﬁcally required for prostatic branching, we took advantageof the fact that mTORC1 is preferentially sensitive to rapamycin inhibi-
tion (Guertin and Sabatini, 2009). Surprisingly, treatment of urogenital
sinus cultures with rapamycin resulted in a consistent increase in pros-
tatic branching, with more numerous and longer prostatic buds visible
after 11 days of culture (Figs. 8A and B; n=4 UGS/condition). Recently,
rapamycin has been reported to result in partial mTORC2 inhibition in
some systems after prolonged exposure or at high concentrations
(Sarbassov et al., 2006; Shor et al., 2008). In our system, using 200 nM
rapamycin, we did not observe evidence of mTORC2 inhibition with
rapamycin after 24 h or 6 days of culture (Fig. 8 and data not shown).
In fact, while rapamycin decreased p-p70S6K levels, consistent with
mTORC1 inhibition, levels of p-AKT(S473) were mildly increased after
rapamycin treatment, by immunoblotting after 24 h (Figs. 8C and D)
and by immunohistochemistry after 11 days (Fig. 8A). This reﬂects an
increase in mTORC2 activity following mTORC1 inhibition, a ﬁnding
that results from the release of an established negative feedback loop
between S6K signaling and PI3K/mTORC2 signaling. (Guertin and
Sabatini, 2007; Manning, 2004; Manning et al., 2005; O'Reilly et al.,
2006). Thus, while these experiments indicate that mTORC1 activity at-
tenuates prostatic branching, it remains possible that the effects of
mTORC1 are indirectly mediated by negative feedback on PI3K/mTORC2
signaling.
Fig. 6. PI3K/mTOR activity is required for efﬁcient epithelial cell migration in mesenchyme-free epithelial cultures. (A) Urogenital sinus epithelial (UGE) tissues from R26ERCre;mT/mG
transgenic mice show mosaic expression of membranous EGFP allowing three-dimensional tracking of epithelial cell migration over time using time-lapse epiﬂuorescence imaging
of mesenchyme-free cultures. While individual cells in vehicle-treated controls demonstrate efﬁcient motility with cytoplasmic protrusions in the direction of migration (top
panels, arrows) as well as readily apparent cell divisions (top panels, arrowheads), LY294002-treated epithelial cells assume an elongated shape with extension and retraction
of protrusions, but are relatively immobile (bottom panels, arrows). (B) Positions of individual epithelial cells can be tracked over time in three dimensions (arrows indicate the
net displacement over a 30 h time period). Individual cell tracks in LY294002-treated UGEs are visibly shorter than those in vehicle controls. Scale bars=100 μm. (C) Net track dis-
placement and mean velocity are signiﬁcantly decreased with LY294002 treatment. Data shown are from one representative experiment out of 5 (n=16–35 cells/condition, error
bars=SEM, p-value using Student's t-test for unpaired samples with unequal variance).
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To distinguish whether mTORC1 modulates prostatic branching
directly or indirectly via feedback to PI3K/mTORC2, we took advantage
of the fact that PI3K, mTORC1 and mTORC2 signaling are all simulta-
neously activated in the setting of PTEN loss, essentially abrogating the
effects of negative feedback between mTORC1 and PI3K/mTORC2
(Manning et al., 2005). If mTORC1 indirectly inhibits prostatic branch-
ing by inhibiting PI3K/mTORC2 signaling, branching should remain
unchanged or even increase in the setting of PTEN loss, despite high
mTORC1 activity. Alternatively, if the inhibitory effects of mTORC1 are
independent of feedback to PI3K/mTORC2 activity, PTEN loss might be
expected to attenuate prostatic branching. Although numerous condi-
tional and prostate-speciﬁc PTEN loss-of-function models exist, all are
driven by prostate-epithelial speciﬁc Cre expression which occurs typi-
cally at P14 or later, when the majority of prostatic branching morpho-
genesis is already completed (Backman et al., 2004; Brunn et al., 1996;
Ratnacaram et al., 2008; Wang et al., 2005). To test whether early em-
bryonic PTEN loss-of-function would alter prostatic branching, we gen-
erated a tamoxifen (4-OHT)-inducible in vitro PTEN loss-of-function
model using the R26ERCremouse line. To verify that robust Cre expres-
sion could be induced in vitro prior to prostatic branching, we crossed
these mice to mT/mG reporter mice, allowing Cre expression to be
tracked by visualization of a membranous EGFP label, while cells nega-
tive for Cre express amembranous RFP (tomato red). After 18 h of organ
culture with 6 μM 4-OHT and DHT, urogenital sinuses (UGS) from Cre-
positive animals (as determined by genotyping) expressed EGFP and
were readily distinguishable from Cre-negative littermates under aﬂuorescent dissecting microscope (data not shown). By day 4 of organ
culture, the timepoint at which the ﬁrst prostatic buds begin to emerge,
we observed nearly uniform Cre expression in the UGS epithelium of
cryosectioned tissues (visualized as membranous EGFP expression)
(Fig. 9A). Relatively less Cre expression was visible in the surrounding
mesenchyme (visualized as membranous tomato red expression).
Importantly, although estrogen signaling is known to affect prostatic
morphogenesis (Huang et al., 2005), prolonged culture in 6 μM 4-OHT
did not have any signiﬁcant independent effects on in vitro prostatic
branching (as demonstrated by the PTEN+/+ UGS in Fig. 9C), and 4-
OHT only showed toxic effects at a dose of 100 μM or above (BWS,
unpublished observations).
We then generated R26ERCre;PTENloxp/loxp embryos (PTEN−/−)
and PTENloxp/loxp littermate controls (PTEN+/+). Culture of UGS
from R26ERCre;PTENloxp/loxp embryos for 7 days in DHT after the addi-
tion of 6 μM 4-OHT resulted in near total loss of PTEN protein as dem-
onstrated by immunoblotting, and dramatically increased levels of
PI3K signaling (measured by p-AKT T308), mTORC1 signaling (mea-
sured by p-p70S6K) and mTORC2 signaling (measured by p-AKT
S473) (Fig. 9B). Importantly, compared to littermate PTEN+/+ con-
trols cultured in identical conditions with 4-OHT, we observed a sig-
niﬁcant decrease in mean bud number and length in PTEN−/− UGS
(Figs. 9C and D; n=5–16 UGS/condition). Because these experiments
do not formally exclude the possibility that PTEN loss results in de-
creased prostatic branching speciﬁcally in the context of altered estro-
genic signaling due to 4-OHT, we also cultured wildtype E15.5 UGS in
a vanadate compound known to inhibit PTEN phosphatase activity,
bpV(pic) (Schmid et al., 2004) (Supplementary Fig. 2). In these
Fig. 7. Speciﬁc inhibition of mTOR kinase without PI3K inhibition abrogates prostatic branching and phenocopies combined PI3K/mTOR inhibition. (A) Treatment of male urogenital sinus
(UGS) tissues with either of two different mTOR kinase inhibitors (1000 nM torin1 or 80 μM DMK-1) for 5–7 days results in decreased prostatic branching grossly identical to that
seen after 25 μM LY294002 treatment. Arrowheads indicate prostatic branches in vehicle control, while seminal vesicle morphogenesis is grossly unaffected by any inhibitors (ar-
rows). Images are representative of 3 independent experiments. (B) Histologic sectioning of urogenital sinuses treated with DMK-1 for 5 days reveals absence of invasive and elon-
gated epithelial buds (arrows), as compared to vehicle-treated controls. (C) Immunoblotting of UGS tissues treated for 24 h with mTOR kinase inhibitors demonstrates decreased
mTORC1 signaling (represented by decreased p-p70S6K levels) and mTORC2 signaling (represented by decreased p-AKT[S473] levels), while PI3K signaling (as measured by p-AKT
[T308] levels) remains unchanged. (D) Quantitation of immunoblot from (B); n=3 independent experiments, 3 UGS/condition/experiment.
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also resulted in abrogated prostatic branching, suggesting that PTEN
activity may be required for prostatic morphogenesis independent
of estrogenic signaling status. Finally, to demonstrate that the effect
of PTEN-inactivation on prostatic branching was speciﬁcally due to in-
creased mTORC1 activity, we returned to our genetic inactivation sys-
tem. We treated PTEN−/− samples with rapamycin and found that
mTORC1 inhibition restored epithelial branching in the context of
PTEN loss (Figs. 9C and D). Strikingly, PTEN−/− UGS samples treated
with rapamycin not only recovered prostatic branching, but branched
even more robustly than wildtype samples, an effect we hypothesize
is attributable to the increased baseline level of PI3K/mTORC2 signal-
ing in these samples. We conclude from these experiments that the
inhibitory effects of mTORC1 activity on prostatic branching are inde-
pendent of the feedback loop between mTORC1 and PI3K/mTORC2
signaling. Given that combined PI3K/mTOR inhibitors and speciﬁc
mTOR kinase inhibitors similarly attenuate prostatic branching, our
data are compatible with a model wherein PI3K/mTORC2 signaling
is required for prostatic branching, while mTORC1 signaling negative-
ly regulates the same process. This strongly suggests that the overall
balance of mTORC1 and PI3K/mTORC2 signaling is a critical regulator
of prostatic morphogenesis.Discussion
In this study, we have shown that PI3K/mTOR signaling is activat-
ed in the invading epithelial buds during prostatic development and
required for prostatic ductal morphogenesis. Consistent with a specif-
ic role in developing prostate epithelial cells, the p110α catalytic sub-
unit of PI3K is up-regulated in response to androgen exposure in the
emerging prostatic buds. Immunoblotting for p-AKT(T308), as well as
imaging in mice transgenic for the PIP3 biosensor, demonstrate that
PI3K is active in the developing prostate and concentrated in the inva-
sive epithelium. Similarly, p-AKT(S473) localization in the prostatic
buds suggests a role for downstream mTORC2 signaling in prostatic
morphogenesis. In accordance with the epithelial activation of PI3K/
mTOR signaling during prostatic development, combined inhibition
of PI3K and mTOR kinase results in a dramatic decrease in epithelial
buds and ductal elongation in whole organ cultures, with minimal
phenotypic variability. Instead of invasive, ﬁnger-like protrusions
into the surrounding mesenchyme, samples exposed to PI3K/mTOR
inhibitors show a broad, pushing epithelial border with the mesen-
chymal tissue. Similarly, in mesenchyme-free urogenital sinus epithe-
lial cultures, PI3K/mTOR inhibition results in absent lobe formation
with abortive branching. Thus, PI3K/mTOR signaling plays a critical
Fig. 8. Speciﬁc inhibition of mTORC1 increases the number and length of prostatic branches. (A) Culture of E15.5 urogenital sinus (UGS) tissues in 200 nM rapamycin results in increased
numbers of prostatic branches (top panels, arrowheads) by day 11 of culture. Excess branches in rapamycin-treated specimens are highlighted on cytokeratin 14 (CK14) immuno-
stained histologic sections (middle panels, arrowheads, 200× magniﬁcation). Immunohistochemistry for pAKT(S473) after 11 days of culture in rapamycin reveals increased
mTORC2 activity in prostatic buds relative to vehicle-treated control (bottom panels, 200× magniﬁcation). (B) Quantiﬁcation of bud number and length in day 11 samples
(n=4 UGS/condition, error bars=SEM, p-value using Student's t-test for unpaired samples with unequal variance). (C and D) Immunoblots with quantiﬁcation of vehicle- and
rapamycin-treated UGS tissues after 24 h of culture reveals decreased mTORC1 activity (p-p70S6K levels), and slightly increased mTORC2 activity (p-AKT[S473]) levels, consistent
with rapamycin-mediated relief of negative feedback between p70S6K and mTORC2 signaling; n=3 independent experiments, 3 UGS/condition/experiment.
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mesenchyme and extracellular matrix.
To our knowledge, this study is the ﬁrst to demonstrate that PI3K/
mTOR signaling regulates prostate epithelial motility during develop-
ment, an intriguing ﬁnding given the frequent up-regulation of this sig-
naling pathway in human prostate tumors (Taylor et al., 2010).
Surprisingly we found that the cellular mechanismmediating the effect
of PI3K/mTOR inhibition on prostate epithelial invasion is not altered
rates of proliferation, apoptosis or impaired epithelial speciﬁcation.
Rather, PI3K/mTOR signaling regulates prostate epithelial cellmigration
in response to growth factor stimulation. Using a novel mesenchyme-
free culture system that supports prostate lobe formation and branch-
ing, we were able to measure three-dimensional epithelial cell motility
during prostatic development. We found that LY294002-treated uro-
genital sinus epithelial cells assumed an elongated shape, and although
they did display intermittent cytoplasmic protrusions, their net dis-
placement and mean speed over time was signiﬁcantly lower thancontrols. This decrease in the efﬁciency of epithelial motility may in
part account for our observation that epithelial nuclei were more
crowded in PI3K/mTOR-inhibited urogenital sinus samples (Fig. 3D). If
epithelial cell proliferation continues at a similar rate in LY294002-
treated samples, but the epithelial cells donot efﬁciently invade andmi-
grate into the surrounding mesenchyme, epithelial cell density might
be expected to increase.
Overall, our ﬁnding that PI3K/mTOR signaling regulates prostate
epithelial migration after growth factor exposure is consistent with
extensive data collected from single cell systems. In Dictyostelium,
directedmigration towards a chemotactic gradient of cAMP is accompa-
nied by accumulation of PIP3 (mediated by PI3K activity) on the leading
plasma membrane, while PTEN is sequestered in the back of the cell
(Iijima and Devreotes, 2002; Iijima et al., 2002). Although chemotaxis
still occurs in the presence of LY294002, or in cells lacking all ﬁve Dic-
tyostelium PI3K genes, strong chemotactic gradients are required and
directional migration is slower and less efﬁcient (Kolsch et al., 2008).
Fig. 9. PTEN loss-of-function decreases prostatic epithelial bud number and length in an mTORC1-dependent fashion. (A) Cre is efﬁciently induced prior to extensive prostatic branching in
E15.5 R26ERCre; mT/mG reporter mouse urogenital sinus (UGS) tissues cultured for 4 days in 6 μM 4-OHT. Vehicle-treated control UGS tissues express a membrane-bound tomato
red ﬂuorophore using the mT/mG reporter allele, consistent with the absence of inducible Cre expression (left panel, merged image), while 4-OHT-treated UGS epithelial cells express
membrane-bound EGFP, consistent with Cre expression in themajority of cells (middle panel, merged image). Only small epithelial buds are visible in in vitro cultures at this early time-
point (right panel, merged image). The mesenchymal cells in the 4-OHT-treated specimens demonstrate a lower level of inducible Cre than the epithelial cells (middle and right panels,
merged images). (B) Immunoblotting for PTEN and PI3K/mTOR signaling components in PTENﬂ/ﬂ (PTEN+/+) and R26ERCre;PTENﬂ/ﬂ (PTEN−/−) UGS tissues treated with 4-OHT for
7 days during in vitro organ culture. PTEN protein is dramatically decreasedwhile PI3K andmTOR signaling is increased in UGS specimenswith inducible PTEN loss (PTEN−/−). (C) Pros-
tatic budnumber and length are decreased by inducible PTEN loss-of-function and this effect is reversible bymTORC1 inhibitionwith rapamycin (n=5–16UGS/condition, error bars=SEM,
*pb0.01; **pb0.0001; ***pb0.01 using Student's t-test for unpaired samples with unequal variance).
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genetic inactivation of PI3Kγ also migrate more slowly towards an
fMLP gradient compared to controls (Ferguson et al., 2007). Intriguingly,
in several recent studies, TORC2 signaling has been shown to be an addi-
tional critical regulator of directed single cell migration, functioning in
parallel with PI3K signaling modules (Cai et al., 2010; Charest et al.,
2010; Liu et al., 2010). Although it has been known for some time that
Dictyosteliummutant for Pianissimo (the homologue ofmammalian rictor,
a required component of TORC2) fail to chemotax, two independent
reports have detailed a PIP3-independent pathway by which chemoat-
tractant leads to the activation of TORC2 at the leading edge of the cell
membrane, activating PKB-mediated downstream signaling events that
are restricted to the cell's leading edge even in the absence of PIP3 (Cai
et al., 2010; Charest et al., 2010). This pathway is independent of PI3K sig-
naling, and may be especially important for cell migration under condi-
tions of particularly low or high PIP3 levels (Cai et al., 2010). As with
PIP3-dependent chemotaxis, this pathway is also highly conserved and
recent work has documented that it plays an important role in mamma-
lian neutrophil chemotaxis (Liu et al., 2010).
Although there is abundant evidence linking PI3K/mTOR signaling
to directed cell migration in single cell systems, there are only limited
data to suggest that the role of these pathways is conserved during mi-
gration of multicellular epithelial structures during organogenesis. In
one of the ﬁrst studies to address the question of PI3K involvement in
epithelial chemotaxis during mammalian development, Tang et al.
found that MDCK cells migrating towards a gradient of GDNF activate
PI3K and that LY294002 exposure blocks chemotaxis in this cell line sys-
tem. To conﬁrm these results using amulticellular tissue, they also dem-
onstrated that directed migration of ureteric bud tissue towards a
localized source of GDNF is abrogated by LY294002 exposure. Similarly,a number of studies have demonstrated that PIP3 accumulation at the
leading edge of the cell is conserved during kidney cell migration.
Using MDCK cells in three dimensional cultures, Yu et al. demonstrated
that HGF exposure results in PIP3 accumulation in cytoplasmic exten-
sions that form prior to chain migration (Yu et al., 2003). Along the
same lines, an additional study found that Ret9 kidney cells localize
PIP3 to cytoplasmic extensions oriented towards a GDNF coated bead,
and ectopic PTEN expression inhibits this directed cell migration
(Tang et al., 2002).
While these studies suggest that PI3K signaling may regulate the
directed migration of multicellular epithelial tissues in much the same
way as in single cell systems, none directly examined whether mTORC2
signaling may play a similar role. Our ﬁnding that speciﬁc mTOR kinase
inhibitors block prostate budding as effectively as combined PI3K/
mTOR inhibition strongly suggests that mTORC2 signaling may play an
equally important role as PI3K in regulating epithelial migration during
development. Although we did not explicitly address the question of
whethermTORC2 inactivation can impair prostatic epithelial cell motility
during development in the absence of PI3K and/or mTORC1 inhibition,
future genetic inactivation studies may be useful to resolve this question.
GermlinemTORC2-loss-of-function in themouse is embryonic lethal, but
the recent availability of mice with a conditional null allele of rictor, a
required component of mTORC2 makes it now feasible to systematically
examine the role of mTORC2 in epithelial morphogenesis in any number
of systems (Shiota et al., 2006).
Although PI3K/mTORC2 signaling is required for prostatic branch-
ing, our study also reveals a novel inhibitory role for mTORC1 signaling
during branching morphogenesis. Our ﬁnding that speciﬁc mTORC1
inhibition leads to increased and longer prostatic buds is especially sur-
prising given that mTOR kinase inhibition has the opposite effect.
341S. Ghosh et al. / Developmental Biology 360 (2011) 329–342Because mTORC1 inhibition activates PI3K/mTORC2 signaling through
eradication of a well-characterized negative feedback loop, we hypoth-
esized that the apparent inhibitory effects of mTORC1might bemediat-
ed by decreased PI3K/mTORC2 signaling. However, when we used a
conditional PTEN loss-of-function model to simultaneously activate
mTORC1 and PI3K/mTORC2 signaling, we still observed a mTORC1-
dependent decrease in prostatic budding. Thus, we conclude that
mTORC1 inhibits prostatic branching through a mechanism indepen-
dent of the known negative feedback loop between mTORC1 and
PI3K/mTORC2. Interestingly, a recent study of lung morphogenesis
revealed that this inhibitory role of mTORC1 is likely conserved in mul-
tiple organ systems. Scott et al. found that rapamycin treatment of fetal
lung explants led to a dramatic increase in airway epithelial surface
complexity, a measure of airway branching (Scott et al., 2010), and
we have had similar ﬁndings in a breast branching morphogenesis sys-
tem (unpublished data). Although the mechanism by which mTORC1
suppresses epithelial branching is unclear at this point,mTORC1 activity
is known to stimulate differentiation and/or exhaustive proliferation of
stem/progenitor cells in multiple systems (Castilho et al., 2009; Chen
et al., 2008; Gan et al., 2008; Sun et al., 2010). It is tempting to speculate
thatmTORC1-driven progenitor cell depletionmay play a similar role in
limiting epithelial branching morphogenesis.
Finally, the fact that mTORC1 plays an inhibitory role in branching,
while the inter-related PI3K/mTORC2 signaling pathway plays a permis-
sive role might at ﬁrst seem surprising. However a number of recent
studies suggest that in many systems the outcome of mTOR activity
may be entirely dependent on the signaling complex with which it is
associated. For example, during T cell development, mTORC1 activity
directs T(H)1 and T(H)17 differentiationwhilemTORC2 has the opposite
effect, enabling T(H)2 differentiation (Delgoffe et al., 2011).mTORC1 and
mTORC2 likely exist in a state ofmutual inhibition resulting fromcompe-
tition for mTOR kinase and numerous negative feedback loops (Hwang
et al., 2008). In this way, the balance of mTORC1 and mTORC2 activity
mayprovide a natural homeostaticmechanism thatmodulates a number
of developmental processes, ranging from differentiation to branching
morphogenesis.
Taken together, our ﬁndings have important potential implications
for understanding the signaling pathways that regulate prostate cancer
invasion and motility. There is little doubt that embryonic prostate de-
velopment and prostatic tumorigenesis, both processes inwhich the ep-
ithelium invades surrounding stroma, bear striking resemblance to one
another, both on a morphologic and gene expression level (Pritchard
et al., 2009; Schaeffer et al., 2008). In this way, studies of each process
can informwork on the other. Importantly, PI3K/mTOR signaling is fre-
quently aberrantly activated in prostate tumors, most commonly by
PTEN inactivation (Taylor et al., 2010) and many of the genes up-
regulated during prostatic tumorigenesis in the PTEN−/− mouse
model map to the branchingmorphogenesis stage of prostatic develop-
ment (Pritchard et al., 2009). Our data extend these ﬁndings to suggest
that some of the same signaling pathways may be required for both
prostatic morphogenesis and tumorigenesis. Perhaps surprisingly
given the frequency of PTEN loss in prostatic tumors, we found that
PTEN loss by itself inhibited prostatic epithelial invasion into stroma
during development. While our genetic recombination system pre-
cludes us from deﬁnitively determining whether this effect of PTEN
loss occurs only in the presence of 4-OHT (which alters estrogenic sig-
naling), we found that PTEN loss actually increased epithelial branching
in the context of lowmTORC1 activity. An important question for future
research is whether this ﬁnding holds true during tumorigenesis. Does
PI3K/mTORC2 activation in the absence of mTORC1 activity enhance
the efﬁciency of prostate tumor cell invasion? Our data predict that
PI3K andmTORC2 inhibitorsmight be particularly effective for blocking
prostate tumor invasion. Along these lines, a recent study has estab-
lished that mTORC2, but not mTORC1, activity is required for prostatic
tumorigenesis in the PTEN−/−mousemodel (Guertin et al., 2009). Fur-
ther, a number of clinical trials have suggested that pharmacologicinhibition of mTORC1 signaling is insufﬁcient as a monotherapy for
solid tumors (Guertin and Sabatini, 2009). Based on data presented
here, we would predict that mTORC1 inhibitor treatment might not
only be ineffective, but might have the paradoxical effect of enhancing
tumor invasion in prostate cancer, particularly in the setting of PTEN
inactivation. Future work will focus on testing these hypotheses in ge-
netically engineered mouse tumor models and human tumor samples.
Supplementary materials related to this article can be found online
at doi:10.1016/j.ydbio.2011.09.027.
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